What are the therapeutic benefits of Δ9‑tetrahydrocannabinol (THC) and the recommended oral and inhaled dosing protocols, including contraindications and monitoring?

Therapeutic Benefits of THC

THC (Δ9-tetrahydrocannabinol) has proven therapeutic benefits primarily for refractory chemotherapy-induced nausea and vomiting when added to guideline-concordant antiemetic regimens, with moderate-quality evidence supporting synthetic cannabinoids (dronabinol, nabilone) and low-quality evidence for THC:CBD extracts. 1

Evidence-Based Therapeutic Indications

Chemotherapy-Induced Nausea and Vomiting (CINV)

• Adults with cancer experiencing refractory CINV despite optimal prophylaxis may use dronabinol, nabilone, or oral 1:1 THC:CBD extract as salvage antiemetics. 1
• A 2020 phase II trial demonstrated oral THC 2.5 mg:CBD 2.5 mg achieved 25% complete response rates versus 14% with placebo (relative risk 1.77), with 83% of patients preferring the cannabinoid regimen. 1
• Evidence quality is moderate for dronabinol and nabilone, but most supporting studies predate modern triple/quadruple antiemetic prophylaxis regimens. 1

Pain Management

• Nabiximols showed moderate-quality evidence for cancer pain relief, though the effect size was modest. 1
• A 2020 study using a metered-dose inhaler delivering 0.5-1 mg THC demonstrated significant pain reduction in neuropathic pain/CRPS patients with minimal cognitive impairment. 2
• Recent 2026 data showed THC/CBD (1:1 ratio, 10 mg/day) reduced VAS pain scores from 7.35 to 3.50 in temporomandibular disorder patients, with functional pain dropping approximately 90%. 3

Other Potential Benefits

• Sleep improvement: Moderate-quality evidence supports oral cannabinoids (nabiximols or nabilone) for sleep in patients with chronic cancer pain. 1
• Appetite/weight: Low-quality evidence exists for dronabinol, nabilone, and THC/CBD extracts; a meta-analysis in HIV/AIDS showed moderate effect on weight gain (SMD 0.57). 1, 4
• Quality of life, anxiety, depression: Evidence remains very low to low quality and insufficient to recommend use. 1

Dosing Protocols

Oral Administration

• Dronabinol: Start 2.5 mg three times daily, titrate up to 10 mg three to four times daily as needed. 1
• Nabilone: Initiate 1 mg twice daily, titrate to maximum 2 mg four times daily. 1
• THC:CBD extract (1:1): Begin 2 mg/day in first week, increase by 2 mg/week until reaching 10 mg/day by fifth week. 3
• Bioavailability: Oral THC absorption is 4-12%, with onset 30 minutes to 2 hours and duration 5-8 hours. 1
• Critical warning: High-fat meals significantly increase oral cannabinoid absorption and may exacerbate side effects; patients must avoid "stacking doses" due to delayed onset (≥1 hour). 1

Inhaled Administration

• Bioavailability: Inhaled THC absorption is 10-35%, with onset in seconds to minutes and duration 2-3 hours. 1
• Metered-dose inhaler: 0.5-1 mg THC per inhalation produces dose-dependent analgesia with Cmax of 14.3-33.8 ng/mL and Tmax of 3.7-4.4 minutes. 2
• General recommendation: Evidence-based guidelines do not recommend inhaled or high-potency cannabis (≥10% or 10 mg THC) for medical purposes due to increased risks. 4

Titration Strategy

• "Start low, go slow" approach is mandatory: Begin at lowest possible dose and increase gradually over up to two weeks. 1
• Maximum daily THC: Generally limit to 30 mg/day or less to avoid psychoactive sequelae and tolerance development. 5
• Risk thresholds for cannabis use disorder: Adults should stay below 8.26 standard THC units/week (1 unit = 5 mg); adolescents below 6.04 units/week. 6

Contraindications and High-Risk Situations

Absolute Contraindications

• Pregnancy: Avoid use entirely. 4
• Schizophrenia or psychotic disorders: Risks clearly outweigh benefits. 4
• Active ischemic heart disease: Daily cannabis use increases risk of coronary heart disease (2.0% vs 0.9%), myocardial infarction (1.7% vs 1.3%), and stroke (2.6% vs 1.0%). 4

Relative Contraindications

• Checkpoint inhibitor therapy: The 2022 MASCC guideline suggests cannabinoids may be considered for refractory CINV only in patients NOT on checkpoint inhibitors. 1
• Advanced age with polypharmacy: Adverse effects and drug interactions pose significant dose-limiting barriers. 1
• High-potency cannabis use: Associated with increased psychotic symptoms (12.4% vs 7.1%) and generalized anxiety disorder (19.1% vs 11.6%) compared to low-potency products. 4

Drug Interactions and Monitoring

Cytochrome P450 Interactions

• THC inhibits: CYP3A4, UGT1A9, UGT2B7, CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2C19. 1
• Very high-risk interaction: Warfarin (requires close INR monitoring). 1
• High-risk interactions: Buprenorphine and tacrolimus. 1
• Chemotherapy interactions: Potential to increase toxicity or decrease potency of cytochrome P450-metabolized agents, though limited clinical data exist. 1

Adverse Effects Requiring Monitoring

• Common (dose-dependent): Euphoria, drowsiness, dizziness, vertigo, hallucinations, mood changes. 1
• In CINV trial: Sedation (19%), dizziness (10%), disorientation (3%). 1
• High-dose CBD (≥300 mg/day): Risk of reversible liver enzyme abnormalities; not recommended outside clinical trials. 1
• Cannabis use disorder: 29% of individuals using cannabis for medical purposes meet DSM-5 criteria for cannabis use disorder. 4

Harm Reduction Strategies

• Avoid concurrent use with alcohol or CNS depressants (especially benzodiazepines). 4
• Do not drive or operate machinery during treatment. 4
• Use lowest effective dose. 4
• Monitor for signs of tolerance, dependence, or psychiatric symptoms. 5, 4

Critical Limitations

Insufficient Evidence Areas

• Cancer-directed treatment: Clinicians should recommend AGAINST using cannabis or cannabinoids as cancer-directed therapy outside clinical trials. 1
• Acute pain and insomnia: Evidence from randomized trials does not support use for these conditions. 4
• Radiation-induced nausea: Studies from the 1980s showed no clear benefit. 1
• Cachexia: The 2020 ASCO cachexia guideline provides weak recommendation AGAINST cannabinoids for treating cachexia in advanced cancer. 1

Pharmacokinetic Variability

• Considerable individual variability in Cmax and tmax exists, particularly with oral administration. 7
• Individualized dose adjustment is essential to avoid side effects and maximize therapeutic response. 7
• Lipid solubility leads to adipose tissue accumulation with gradual release during periods of adipose breakdown (common in cancer patients). 1